The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2022 | Update from CHRYSALIS: amivantamab in patients with NSCLC with MET exon 14 skipping mutation
Matthew Krebs, MBChB, MRCP, PhD, The Christie NHS Foundation Trust, Manchester, UK, discusses updated results from CHRYSALIS (NCT02609776), an ongoing Phase I dose escalation/dose expansion study of amivantamab, a fully human bispecific antibody targeting epidermal growth factor receptor (EGFR) and MET, in patients with non-small cell lung cancer (NSCLC) with MET exon 14 skipping mutation. Amivantamab is currently used to treat EGFR exon 20 mutated NSCLC, but it’s potential is now being explored in those with MET-mutated disease. The trial reported an overall response rate of 33%, with patients who had no prior treatment achieving a response rate of 57%, and patients who had received prior treatment but not with a MET inhibitor achieving a response rate of 47%. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.
